Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dimebon Open-Label Extension in Alzheimer's Disease
NCT01152216Phase 3Terminated
- Sponsor
- Medivation
- Start
- Apr 2010
- Primary completion
- May 2012
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
01
Overview
Phase 3, open-label, single-arm trial of latrepirdine in Alzheimer's disease (AD), sponsored by Medivation. Primary endpoint: Safety. Started Apr 2010; status: terminated.
02
Drugs
latrepirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01152216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01152216.